Rogelio Pérez-Padilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rogelio Pérez-Padilla has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Christian Rolfo
The Ohio State University Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), Columbus, OH, USA
2 shared publications - Diego de Miguel-Perez
Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY 11776, USA
2 shared publications - Eunice Romero-Nuñez
Laboratorio de Medicina Personalizada, Instituto Nacional de Cancerología, S.S.A., San Fernando 22 Sección XVI, Tlalpan, Mexico City 14080, Mexico
2 shared publications - Jose Luis Maravillas-Montero
Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México
2 shared publications Maria Montes de Oca
Universidad Central de Venezuela, Hospital Centro Médico de Caracas, Caracas, Venezuela
2 shared publications- Marisol Arroyo-Hernández
Thoracic Oncology Unit, Instituto Nacional de Cancerología, S.S.A., San Fernando 22 Sección XVI, Tlalpan, Mexico City 14080, Mexico
2 shared publications
Latest Publications
- Open Access
Correction: Hernández-Pedro et al. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies. Vaccines 2023, 11, 1612
The authors would like to make the following corrections to this published paper
Open AccessCorrection: Hernández-Pedro et al. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies. Vaccines 2023, 11, 1612
The authors would like to make the following corrections to this published paper
- Top Cited Papers
- 17 July 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (8) , 709-724
The global burden of COPD: epidemiology and effect of prevention strategies
- 17 July 2025
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 13 (8) , 709-724
Top Cited PapersThe global burden of COPD: epidemiology and effect of prevention strategies
- Open Access
Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies
Immune dysregulation and cancer treatment may affect SARS-CoV-2 vaccination protection. Antibody production by B-cells play a vital role in the control and clearance of the SARS-CoV-2 virus. This study prospectively explores B-cell seroconversion following SARS-CoV-2 immunization in healthy individuals and non-small cell lung cancer (NSCLC) patients undergoing oncological treatment. 92 NSCLC patients and 27 healthy individuals’ blood samples were collected after receiving any COVID-19 vaccine. Serum and mononuclear cells were isolated, and a serum surrogate virus neutralization test kit evaluated SARS-CoV-2 antibodies. B-cell subpopulations on mononuclear cells were characterized by flow cytometry. Patients were compared based on vaccination specifications and target mutation oncological treatment. A higher percentage of healthy individuals developed more SARS-CoV-2 neutralizing antibodies than NSCLC patients (63% vs. 54.3%; p = 0.03). NSCLC patients receiving chemotherapy (CTX) or tyrosine kinase inhibitors (TKIs) developed antibodies in 45.2% and 53.7%, of cases, respectively, showing an impaired antibody generation. CTX patients exhibited trends towards lower median antibody production than TKIs (1.0, IQR 83 vs. 38.23, IQR 89.22; p = 0.069). Patients receiving immunotherapy did not generate antibodies. A sub-analysis revealed that those with ALK mutations exhibited non-significant trends towards higher antibody titers (63.02, IQR 76.58 vs. 21.78, IQR 93.5; p = 0.1742) and B-cells quantification (10.80, IQR 7.52 vs. 7.22, IQR 3.32; p = 0.1382) against the SARS-CoV-2 spike protein than EGFR patients; nonetheless, these differences were not statistically significant. This study shows that antibodies against SARS-CoV-2 may be impaired in patients with NSCLC secondary to EGFR-targeted TKIs compared to ALK-directed treatment.
Open AccessImpact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies
Immune dysregulation and cancer treatment may affect SARS-CoV-2 vaccination protection. Antibody production by B-cells play a vital role in the control and clearance of the SARS-CoV-2 virus. This study prospectively explores B-cell seroconversion following SARS-CoV-2 immunization in healthy individuals and non-small cell lung cancer (NSCLC) patients undergoing oncological treatment. 92 NSCLC patients and 27 healthy individuals’ blood samples were collected after receiving any COVID-19 vaccine. Serum and mononuclear cells were isolated, and a serum surrogate virus neutralization test kit evaluated SARS-CoV-2 antibodies. B-cell subpopulations on mononuclear cells were characterized by flow cytometry. Patients were compared based on vaccination specifications and target mutation oncological treatment. A higher percentage of healthy individuals developed more SARS-CoV-2 neutralizing antibodies than NSCLC patients (63% vs. 54.3%; p = 0.03). NSCLC patients receiving chemotherapy (CTX) or tyrosine kinase inhibitors (TKIs) developed antibodies in 45.2% and 53.7%, of cases, respectively, showing an impaired antibody generation. CTX patients exhibited trends towards lower median antibody production than TKIs (1.0, IQR 83 vs. 38.23, IQR 89.22; p = 0.069). Patients receiving immunotherapy did not generate antibodies. A sub-analysis revealed that those with ALK mutations exhibited non-significant trends towards higher antibody titers (63.02, IQR 76.58 vs. 21.78, IQR 93.5; p = 0.1742) and B-cells quantification (10.80, IQR 7.52 vs. 7.22, IQR 3.32; p = 0.1382) against the SARS-CoV-2 spike protein than EGFR patients; nonetheless, these differences were not statistically significant. This study shows that antibodies against SARS-CoV-2 may be impaired in patients with NSCLC secondary to EGFR-targeted TKIs compared to ALK-directed treatment.
- 1 March 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (3) , 172-178
Comparing Spirometric Reference Values From Childhood to Old Age Estimated by LMS and Linear Regression Models
- 1 March 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (3) , 172-178
Comparing Spirometric Reference Values From Childhood to Old Age Estimated by LMS and Linear Regression Models
- 1 January 2021
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 80 (2) , 132-140
Telemedicina durante la pandemia por COVID-19
- 1 January 2021
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 80 (2) , 132-140
Telemedicina durante la pandemia por COVID-19
- 1 January 2021
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 80 (1) , 4-5
Reforzar la prevención ante el crecimiento de casos y la amenaza de la nueva variante del SARS-CoV-2
- 1 January 2021
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 80 (1) , 4-5
Reforzar la prevención ante el crecimiento de casos y la amenaza de la nueva variante del SARS-CoV-2
- 1 January 2020
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 79 (2) , 69-70
¿Qué tan silenciosa es la hipoxemia en COVID-19?
- 1 January 2020
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 79 (2) , 69-70
¿Qué tan silenciosa es la hipoxemia en COVID-19?
- Open Access
- 26 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0121832
Instability in the COPD Diagnosis upon Repeat Testing Vary with the Definition of COPD
A low FEV1/FVC from post-bronchodilator spirometry is required to diagnose COPD. Both the FEV1 and the FVC can vary over time; therefore, individuals can be given a diagnosis of mild COPD at one visit, but have normal spirometry during the next appointment, even without an intervention. We analyzed two population-based surveys of adults with spirometry carried out for the same individuals 5-9 years after their baseline examination. We determined the factors associated with a change in the spirometry interpretation from one exam to the next utilizing different criteria commonly used to diagnose COPD. The rate of an inconsistent diagnosis of mild COPD was 11.7% using FEV1/FVC 1/FEV6 1. Using FEV1/FEV6 <LLN or GOLD stage 2-4 as the criterion for airflow obstruction reduces inconsistencies in the diagnosis of mild COPD. Further improvement could be obtained by defining a borderline zone around the LLN (e.g. plus or minus 0.6 SD), or repeating the test in patients with borderline results.
- 26 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0121832
Open AccessInstability in the COPD Diagnosis upon Repeat Testing Vary with the Definition of COPD
A low FEV1/FVC from post-bronchodilator spirometry is required to diagnose COPD. Both the FEV1 and the FVC can vary over time; therefore, individuals can be given a diagnosis of mild COPD at one visit, but have normal spirometry during the next appointment, even without an intervention. We analyzed two population-based surveys of adults with spirometry carried out for the same individuals 5-9 years after their baseline examination. We determined the factors associated with a change in the spirometry interpretation from one exam to the next utilizing different criteria commonly used to diagnose COPD. The rate of an inconsistent diagnosis of mild COPD was 11.7% using FEV1/FVC 1/FEV6 1. Using FEV1/FEV6 <LLN or GOLD stage 2-4 as the criterion for airflow obstruction reduces inconsistencies in the diagnosis of mild COPD. Further improvement could be obtained by defining a borderline zone around the LLN (e.g. plus or minus 0.6 SD), or repeating the test in patients with borderline results.
- Open Access
- 1 January 2015
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 74 (3) , 179-183
Tendencias de la mortalidad estandarizada por edad y su comparación con las tasas de muerte específicas anuales por grupos de edad y sexo por cáncer pulmonar en México, 2000-2010
RESUMEN. Antecedentes: La descripción de la tendencia en la mortalidad por cáncer pulmonar y de las tasas específi cas por edad y sexo nos permiten describir el comportamiento actual de la enfermedad. Objetivo: Analizar la tendencia de las tasas de mortalidad estandarizadas por edad y las muertes anuales específi cas por edad del cáncer pulmonar. Material y métodos: Para este estudio analizamos las bases de datos ofi ciales de mortalidad para México (INEGI) del período 2000-2010. Nosotros estimamos la tendencia de la mortalidad estandarizada por edad mediante el método directo, utilizando como población estándar la de México durante el año 2010. Calculamos también las causas específi cas de muerte anuales para cáncer pulmonar (Código de la
- 1 January 2015
- Published by Instituto Mexicano del Seguro Social in NCT Neumología y Cirugía de Tórax
- Vol. 74 (3) , 179-183
Open AccessTendencias de la mortalidad estandarizada por edad y su comparación con las tasas de muerte específicas anuales por grupos de edad y sexo por cáncer pulmonar en México, 2000-2010
RESUMEN. Antecedentes: La descripción de la tendencia en la mortalidad por cáncer pulmonar y de las tasas específi cas por edad y sexo nos permiten describir el comportamiento actual de la enfermedad. Objetivo: Analizar la tendencia de las tasas de mortalidad estandarizadas por edad y las muertes anuales específi cas por edad del cáncer pulmonar. Material y métodos: Para este estudio analizamos las bases de datos ofi ciales de mortalidad para México (INEGI) del período 2000-2010. Nosotros estimamos la tendencia de la mortalidad estandarizada por edad mediante el método directo, utilizando como población estándar la de México durante el año 2010. Calculamos también las causas específi cas de muerte anuales para cáncer pulmonar (Código de la